BiotechTube

Metformin + placebo

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Gestational Diabetes Mellitus

Conditions

Gestational Diabetes Mellitus

Trial Timeline

Jan 27, 2015 → Sep 30, 2019

NCT ID
NCT02394158

About Metformin + placebo

Metformin + placebo is a approved stage product being developed by Novo Nordisk for Gestational Diabetes Mellitus. The current trial status is unknown. This product is registered under clinical trial identifier NCT02394158. Target conditions include Gestational Diabetes Mellitus.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02394158ApprovedUNKNOWN

Competing Products

18 competing products in Gestational Diabetes Mellitus

See all competitors
ProductCompanyStageHype Score
somatropinEli LillyPhase 3
77
Insulin LISPRO + Insulin, Long-Acting and InsulinEli LillyApproved
85
Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort BJiangsu Hengrui MedicinePhase 2
52
Pembrolizumab Injection [Keytruda]MerckPhase 2
52
recombinant somatropinMerckPre-clinical
23
Recombinant human growth hormone (r-hGH)MerckPhase 3
77
Avelumab Injection + Methotrexate 1 GM InjectionMerckPhase 1/2
41
Saizen® + Saizen®MerckPhase 3
77
Metformin XR plus placebo + Metformin XR plus liraglutideNovo NordiskPhase 3
76
Somapacitan + Norditropin®Novo NordiskPhase 2
51
Liraglutide + PlaceboNovo NordiskApproved
84
Genotropin (PN-180,307) Somatropin + Control-no treatmentPfizerPhase 3
76
growth hormonePfizerPre-clinical
22
SomatropinPfizerPre-clinical
22
SomatropinPfizerPre-clinical
22
Genotropin (somatropin)PfizerApproved
84
OmnitropeSandoz GroupApproved
82
Inhaled Technosphere InsulinMannKind CorpPhase 2/3
60

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved
84
Liraglutide + SalineApproved
84
Hydrocortisone + PlaceboApproved
84
biphasic insulin aspart + insulin aspartApproved
84
Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved
84